# Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers

> **NCT04969497** · PHASE1 · COMPLETED · sponsor: **Zosano Pharma Corporation** · enrollment: 48 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Treatment A: M207 3.8 mg "MiniMac"
- **DRUG:** Treatment B: M207 3.8 mg "MACAP"
- **DRUG:** Treatment C: 5.0 mg Intranasal Zolmitriptan administered at time = 0 and 2 hours post time 0

## Key facts

- **NCT ID:** NCT04969497
- **Lead sponsor:** Zosano Pharma Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-24
- **Primary completion:** 2021-09-02
- **Final completion:** 2021-09-02
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04969497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04969497, "Study of PK, Safety, and Tolerability of 2 Lots of M207 & Intranasal Zolmitriptan in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04969497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*